Claire Albert

Title: Claire Albert - Innovator in Enhanced Targeting Platforms

Introduction

Claire Albert is a prominent inventor based in New Haven, CT (US). She has made significant contributions to the field of biotechnology, particularly in the development of enhanced targeting platforms. Her innovative work focuses on improving the delivery of therapeutic agents to specific cells, tissues, and organs.

Latest Patents

Claire Albert holds 1 patent for her invention titled "Enhanced Targeting Platform." This platform technology provides particle and nucleic acid conjugates, along with compositions that enhance targeting to cells, tissues, and organs. The technology involves synthetic binding proteins, such as polypeptide monobodies, which are covalently conjugated to the surface of particles or nucleic acids. This allows for the linking of targeting agents to the surfaces of these deliverables. Additionally, the particles can include therapeutic, diagnostic, or prophylactic agents, making them versatile for various applications, including ex vivo perfusion of mammalian organs and in vivo disease treatment.

Career Highlights

Throughout her career, Claire has worked with prestigious institutions, including Yale University and New York University. Her experience in these renowned organizations has allowed her to advance her research and contribute to significant innovations in her field.

Collaborations

Claire has collaborated with notable professionals, including W Mark Saltzman and Gregory T Tietjen. These partnerships have further enriched her work and expanded the impact of her inventions.

Conclusion

Claire Albert is a trailblazer in the field of biotechnology, with her enhanced targeting platform representing a significant advancement in targeted delivery systems. Her contributions continue to influence the landscape of medical technology and therapeutic applications.